3-吡啶-3-基苯甲酸 | 4385-77-7

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-吡啶-3-基苯甲酸
• 中文别名: 3-吡啶-3-苯甲酸；3-(3-吡啶)苯甲酸；3-吡啶-3-基-苯甲酸
• 英文名称: 3-(pyridin-3-yl)benzoic acid
• 英文别名: 3-pyrid-3-ylbenzoic acid；3-pyridin-3-ylbenzoic acid
• CAS: 4385-77-7
• 化学式: C₁₂H₉NO₂
• 分子量: 199.209
• InChiKey: PXASTGBSGPFLFJ-UHFFFAOYSA-N

物化性质

• 熔点：
  202-205.5
• 沸点：
  420.1±28.0 °C(Predicted)
• 密度：
  1.241±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  29333990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将药物存放在避光、通风且干燥的地方，并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Pyridin-3-yl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Pyridin-3-yl)benzoic acid
CAS number: 4385-77-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H9NO2
Molecular weight: 199.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-吡啶-3-基苯甲酸 在 platinum(IV) oxide 盐酸 、 sodium hydroxide 、 氢气 、 三乙胺 作用下， 以 甲醇 、 乙醚 、 水 为溶剂， 反应 29.0h， 生成 3-(1-Propionylpiperidino-3-yl)-benzoic acid
  参考文献：
  名称：

  3-苯基哌啶。中枢多巴胺-自体刺激活性。

  摘要：

  已经合成了三十种与选择性多巴胺-自身受体激动剂3-（3-羟苯基）-Nn-丙基哌啶有关的化合物，并测试了其对中央多巴胺-自身受体的刺激活性。3-（3-羟苯基）哌啶部分似乎对于高效力和选择性是必不可少的。将另外的羟基引入芳族环的4位得到具有多巴胺能活性但对自体受体缺乏选择性的化合物。3-（3-羟基苯基）-Nn-丙基吡咯烷，3-（3-羟基）-Nn-丙基全氢a庚因和3-（3-羟基苯基）喹核苷均无活性。最有效的化合物是N-异丙基，Nn-丁基，Nn-戊基和N-苯乙基取代的3-（3-羟苯基）哌啶衍生物。

  DOI：

  10.1021/jm00144a021
• 作为产物：
  描述：

  3-吡啶硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 水 为溶剂， 反应 18.0h， 生成 3-吡啶-3-基苯甲酸
  参考文献：
  名称：

  Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors

  摘要：

  The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable. Most patients relapse within two years of therapy often due to acquisition of an additional mutation in EGFR kinase domain that confers resistance to TKIs. Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs. Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macro-cyclic TKI. BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFR(del19 T790M C797S) xenograft model. Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the molecule through macrocyclization.

  DOI：

  10.1021/acs.jmedchem.9b01169

文献信息

• Design, synthesis and stepwise optimization of nitrile-based inhibitors of cathepsins B and L
  作者：Lorenzo Cianni、Fernanda Dos Reis Rocho、Vinícius Bonatto、Felipe Cardoso Prado Martins、Jerônimo Lameira、Andrei Leitão、Carlos A. Montanari、Anwar Shamim

  DOI：10.1016/j.bmc.2020.115827

  日期：2021.1

  Human cathepsin B (CatB) is an important biological target in cancer therapy. In this work, we performed a knowledge-based design approach and the synthesis of a new set of 19 peptide-like nitrile-based cathepsin inhibitors. Reported compounds were assayed against a panel of human cysteine proteases: CatB, CatL, CatK, and CatS. Three compounds (7h, 7i, and 7j) displayed nanomolar inhibition of CatB

  人组织蛋白酶 B (CatB) 是癌症治疗中的重要生物学靶点。在这项工作中，我们采用了一种基于知识的设计方法，并合成了一组新的 19 种肽样腈基组织蛋白酶抑制剂。针对一组人半胱氨酸蛋白酶对报告的化合物进行了分析：CatB、CatL、CatK 和 CatS。三种化合物（7h、7i和7j）显示出对 CatB 的纳摩尔抑制以及对 CatK 和 CatL 的选择性。的选择性通过使用的组合来实现对位联苯环在P 3，卤代苯丙氨酸P 2和Thr-O-BZ组在P 1。同样地，化合物7I和7J在所研究的酶组中显示出选择性 CatB 抑制作用。我们还描述了一个成功的例子，用生物等排置换磺酰胺 [ 7e  →  6b ]的酰胺键，我们观察到 CatB 的亲和力和选择性增加，同时降低了化合物的亲脂性 (ilogP)。我们基于知识的设计方法和各自的结构-活性关系为治疗相关组织蛋白酶的特定配体-靶标相互作用提供了见解。
• Deoxygenative Deuteration of Carboxylic Acids with D₂ O
  作者：Muliang Zhang、Xiang-Ai Yuan、Chengjian Zhu、Jin Xie

  DOI：10.1002/anie.201811522

  日期：2019.1.2

  aliphatic carboxylic acids with D2O as an inexpensive deuterium source. The use of Ph3P as an O‐atom transfer reagent can facilitate the deoxygenation of aromatic acids, while Ph2POEt is a better O‐atom transfer reagent for aliphatic acids. The highly precise deoxygenation of complex carboxylic acids makes this protocol promising for late‐stage deoxygenative deuteration of natural product derivatives

  我们报告了从芳族和脂肪族羧酸与D 2 O作为廉价的氘源制备氘代醛的通用，实用和可扩展的方法。Ph 3 P作为O原子转移试剂的使用可以促进芳族酸的脱氧，而Ph 2 POEt是一种更好的脂族酸O原子转移试剂。复杂羧酸的高精度脱氧使该方案有望用于天然产物衍生物和药物化合物的后期脱氧氘代。
• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MER
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2018071343A1

  公开（公告）日：2018-04-19

  Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、R6、R7、R24、X、L、n和p如规范中定义的那样，可用于治疗或预防Mer酪氨酸激酶受体调节的疾病或症状。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。
• Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK)
  作者：Tiancheng Fu、Yingying Zuo、Zhenpeng Zhong、Xuan Chen、Zhengying Pan

  DOI：10.1016/j.ejmech.2021.114051

  日期：2022.2

  understood. Herein, we present the discovery of a novel series of selective and irreversible inhibitors of BLK with nanomolar potency against BLK in biochemical and cellular assays. Compound 25 demonstrated potent antiproliferative activities against several B cell lymphoma cell lines. These compounds constitute the first series of selective inhibitors developed for BLK and could help expedite the exploration

  B 淋巴酪氨酸激酶 (BLK) 是 SRC 家族非受体酪氨酸激酶的成员，参与 B 细胞受体 (BCR) 信号通路和 B 细胞发育和功能。BLK 的失调与自身免疫性疾病和癌症有关。然而，缺乏用于 BLK 的良好工具化合物，并且对 BLK 介导生理和病理过程的分子机制知之甚少。在此，我们展示了一系列新型选择性和不可逆 BLK 抑制剂的发现，这些抑制剂在生化和细胞分析中具有纳摩尔级的 BLK 效力。化合物25证明了对几种 B 细胞淋巴瘤细胞系的有效抗增殖活性。这些化合物构成了为 BLK 开发的第一批选择性抑制剂，有助于加快 BLK 功能的探索。
• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。